FDA Approves Giredestrant Plus Everolimus for ESR1-Mutant Advanced Breast Cancer
On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.
The FDA also authorized the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with giredestrant in combination with everolimus.
evERA
Efficacy was evaluated in the randomized, open-label, multicenter evERA Breast Cancer trial (ClinicalTrials.gov Identifier NCT05306340) in 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 patients whose tumors had ESR1 mutations. Circulating tumor DNA (ctDNA) was assessed centrally to determine ESR1 mutational status using the FoundationOne Liquid CDx assay, limited to specific ESR1 mutations in the ligand binding domain.
Patients were randomly assigned 1:1 to receive giredestrant at 30 mg once daily (n = 183) or physician’s choice of endocrine therapy (n = 190), which included exemestane, fulvestrant, or tamoxifen. Patients in both arms also received everolimus at 10 mg once daily. Pre/perimenopausal female patients received a gonadotropin-releasing hormone (GnRH) agonist for ovarian function suppression; male patients also received a GnRH agonist, except in the case of bilateral orchiectomy. Patients were treated until disease progression or unacceptable toxicity.
The primary efficacy outcome measure was progression-free survival by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1. Additional efficacy endpoints included overall survival and objective response rate. The trial demonstrated a statistically significant improvement in progression-free survival for giredestrant and everolimus compared with physician’s choice of endocrine therapy plus everolimus in patients whose tumors had ESR1 mutations. In the ESR1-mutant population, the hazard ratio for progression-free survival was 0.38 (95% confidence interval [CI] = 0.27–0.54; P < .0001). Median progression-free survival was 10 months (95% CI = 8.1–12.9 months) in the giredestrant and everolimus arm and 5.5 months (95% CI = 3.8–5.6 months) in the physician’s choice of endocrine therapy plus everolimus arm. The objective response rate was 27% (95% CI = 18%–37%) and 14% (95% CI = 8%–22%) in the respective arms. At the time of the progression-free survival analysis, overall survival data were immature.
The most common adverse reactions (occurring in ≥ 20%) in patients receiving giredestrant plus everolimus were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
The most common laboratory abnormalities in patients receiving giredestrant plus everolimus were decreased hemoglobin, decreased lymphocytes, decreased white blood cell count, increased aspartate aminotransferase, increased alanine aminotransferase, decreased neutrophils, decreased platelets, decreased calcium, decreased potassium, increased creatinine, and decreased sodium.
The prescribing information includes warnings and precautions for bradycardia and embryo-fetal toxicity.
Recommended Dosage
The recommended dose for giredestrant is 30 mg taken orally once daily with or without food until disease progression or unacceptable toxicity.
This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence for concurrent submission and review of oncology drugs among international partners. For this review, the FDA collaborated with Health Canada and Israel’s Ministry of Health. The applications may be undergoing the submission process or still be under review at the other regulatory agencies.
This review also used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 4 weeks ahead of the FDA goal date.